Tag Archive: ADHD

Nov
04

Omega 3 and 6 fatty acids supplementation can help children and adolescents who have the inattentive subtype of ADHD called ADD

Omega 3 and 6 fatty acids supplementation can help children and adolescents who have the inattentive subtype of ADHD called ADD, suggest researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden.

Sep
03

A longitudinal study published in the American Academy of Pediatrics’ (AAP)

A longitudinal study published in the American Academy of Pediatrics’ (AAP) journal Pediatrics has shown that stimulant medication given to children being treated for ADHD does not affect their final height in adulthood.

Aug
07

Prenatal exposure to tobacco smoke appears to lead to alterations in the brain similar to those seen with attention–deficit/hyperactivity disorder (ADHD)

Prenatal exposure to tobacco smoke appears to lead to alterations in the brain similar to those seen with attention–deficit/hyperactivity disorder (ADHD), as per a new study in the July issue of JAMA Psychiatry.

Aug
05

Using behavioral interventions to treat children and adolescents with attention–deficit/hyperactivity disorder (ADHD)

Using behavioral interventions to treat children and adolescents with attention–deficit/hyperactivity disorder (ADHD) has the potential to improve both child and parent functioning, suggests a new meta–analysis. The study was published in the August issue of the Journal of the American Academy of Child and Adolescent Psychiatry.

Aug
04

Using behavioral interventions to treat children and adolescents with attention–deficit/hyperactivity disorder (ADHD)

Using behavioral interventions to treat children and adolescents with attention–deficit/hyperactivity disorder (ADHD) has the potential to improve both child and parent functioning, suggests a new meta–analysis. The study was published in the August issue of the Journal of the American Academy of Child and Adolescent Psychiatry.

Jul
25

Smoking during pregnancy and use of nicotine replacement products have been linked to a higher risk of attention–deficit/hyperactivity disorder (ADHD)

Smoking during pregnancy and use of nicotine replacement products have been linked to a higher risk of attention–deficit/hyperactivity disorder (ADHD) in the offspring. Compared to children with nonsmoking parents, kids with two smoking parents were 83% more likely to develop ADHD. The findings were published online July 21 in Pediatrics.

Jul
12

Attention–deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs)

Attention–deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs) are inextricably associated, according to a clinical report from the American Academy of Pediatrics (AAP). The report from AAP, published online in Pediatrics, offers practical strategies for reducing the risk for SUDs in patients with ADHD and suggestions for safe prescribing of stimulant medication.

Jul
04

The risk is even higher when the drugs are used for the treatment of attention–deficit/hyperactivity disorder (ADHD)

A new study published online in the Journal of Child and Adolescent Psychopharmacology has revealed that psychostimulant use in children and adolescents is associated with two–fold increased risk for a cardiovascular event compared with nonuse of the drugs. The risk is even higher when the drugs are used for the treatment of attention–deficit/hyperactivity disorder (ADHD).

Jun
19

Children with attention–deficit/hyperactivity disorder (ADHD)

Children with attention–deficit/hyperactivity disorder (ADHD) have reduced iron levels in the brain, which normalize with stimulant medication, reports a new research conducted by investigators at the Medical University of South Carolina Center for Biomedical Imaging in Charleston. Researchers reported that medication–naive patients with ADHD had significantly lower brain iron levels compared with those who had …

Continue reading »

May
25

• European drug regulators have recommended market approval for dexamfetamine sulfate as a second-line treatment for attention-deficit/hyperactivity disorder (ADHD)

European drug regulators have recommended market approval for dexamfetamine sulfate as a second-line treatment for attention-deficit/hyperactivity disorder (ADHD) in children. Dexamfetamine sulfate is indicated for children with ADHD aged 6 to 17 years who have not responded to methylphenidate.

Older posts «